JOHN BECKNER: Open Payments
NPI 1538212519 · ETON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,818 in 91 payments from 16 companies in 2025. Trend: 2023 $323 · 2024 $1,263 · 2025 $1,818
Food & beverage: $1,818
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 22 | $413 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $356 |
| ABBVIE INC. | 14 | $234 |
| Neurocrine BioSciences, Inc. | 9 | $173 |
| Vanda Pharmaceuticals Inc. | 7 | $125 |
| Lundbeck LLC | 4 | $85 |
| Luye Pharma (USA) Ltd. | 3 | $81 |
| Alkermes, Inc. | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
Products named: CAPLYTA, AUSTEDO XR, VRAYLAR, INGREZZA, UZEDY, FANAPT, REXULTI, ERZOFRI EXTENDED-RELEASE.
Industry payments across GA — which companies pay providers there.
